Implementing Measurable Residual Disease Assessment in Acute Myeloid Leukemia: Methods, Clinical Decisions, and a Tiered Framework for Resource-Limited Settings

Measurable residual disease (MRD) is a well-established prognostic biomarker in acute myeloid leukemia (AML), although randomized evidence that MRD-guided monitoring improves overall survival is so far limited to prespecified molecular subgroups. This review compares current MRD methods (multiparameter flow cytometry, polymerase chain reaction, and next-generation sequencing), outlines their benefits and drawbacks, and discusses the prognostic significance of MRD at different time points during treatment. We summarize the 2025 ELN-DAVID recommendations, which address the integration of MRD status into decisions on treatment escalation or de-escalation and on the timing of allogeneic hematopoietic cell transplantation. We discuss the time points at which MRD should be assessed, including after intensive chemotherapy, after hypomethylating agents combined with venetoclax, and around transplantation. We also discuss open questions in FLT3-mutated and NPM1-mutated disease, including low-level MRD and treatment cessation. Factors affecting the accuracy of MRD assessment are also covered, such as sample hemodilution, peripheral blood testing, and the uneven standardization of flow cytometric and molecular assays. Finally, we consider how to implement MRD assessment when infrastructure, reagents, or downstream interventions are limited, and propose a tiered framework that matches modality to local capability.

Authors

Institutions

Publication Details

Journal
International Journal of Molecular Sciences
Published
2026-11-12
DOI
https://doi.org/10.3390/ijms272210143
Primary Topic
Acute Myeloid Leukemia Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Implementing Measurable Residual Disease Assessment in Acute Myeloid Leukemia: Methods, Clinical Decisions, and a Tiered Framework for Resource-Limited Settings

Nidal M. Almasri, Fareed H. Barakat, Zaid Abdel Rahman, Enas Abusalim et al.
International Journal of Molecular Sciences
Acute Myeloid Leukemia Research
article

Implementing Measurable Residual Disease Assessment in Acute Myeloid Leukemia: Methods, Clinical Decisions, and a Tiered Framework for Resource-Limited Settings

Nidal M. Almasri, Fareed H. Barakat, Zaid Abdel Rahman, Enas Abusalim, Nazmi Kamal, Abdulrahman Shamieh, M. Harb
article en

Abstract

Measurable residual disease (MRD) is a well-established prognostic biomarker in acute myeloid leukemia (AML), although randomized evidence that MRD-guided monitoring improves overall survival is so far limited to prespecified molecular subgroups. This review compares current MRD methods (multiparameter flow cytometry, polymerase chain reaction, and next-generation sequencing), outlines their benefits and drawbacks, and discusses the prognostic significance of MRD at different time points during treatment. We summarize the 2025 ELN-DAVID recommendations, which address the integration of MRD status into decisions on treatment escalation or de-escalation and on the timing of allogeneic hematopoietic cell transplantation. We discuss the time points at which MRD should be assessed, including after intensive chemotherapy, after hypomethylating agents combined with venetoclax, and around transplantation. We also discuss open questions in FLT3-mutated and NPM1-mutated disease, including low-level MRD and treatment cessation. Factors affecting the accuracy of MRD assessment are also covered, such as sample hemodilution, peripheral blood testing, and the uneven standardization of flow cytometric and molecular assays. Finally, we consider how to implement MRD assessment when infrastructure, reagents, or downstream interventions are limited, and propose a tiered framework that matches modality to local capability.

International Journal of Molecular SciencesVol. 27(22)
University of Jordan (JO), King Hussein Cancer Center (JO), Al-Balqa Applied University (JO)
Good health and well-being
Acute Myeloid Leukemia Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon